Neuphoria Therapeutics (NEUP) Operating Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Operating Income of -$1.2 million for Q1 2026, down 110.12% year-over-year from $12.0 million in Q1 2025, and up 70.16% quarter-over-quarter from -$4.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Operating Income (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Operating Income for 4 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 110.12% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$16.8 million (down 2071.23% YoY), while the FY2025 annual figure was -$1.1 million, up 93.69% from the prior year.
- Operating Income advanced to -$1.2 million in Q1 2026 per NEUP's latest filing, from -$4.1 million in the prior quarter.
- Across five years, Operating Income topped out at $12.0 million in Q1 2025 and bottomed at -$5.8 million in Q2 2025.
- Historically, Operating Income has averaged -$2.7 million across 4 years, with a median of -$4.1 million in 2025.
- Annual changes were most pronounced in 2025 — Operating Income surged 600.29% — and 2026, when it slumped 110.12%.
- Neuphoria Therapeutics' Operating Income stood at -$4.6 million in 2023, then rose by 18.66% to -$3.7 million in 2024, then declined by 9.65% to -$4.1 million in 2025, then surged by 70.16% to -$1.2 million in 2026.
- Business Quant data shows NEUP's Operating Income at -$1.2 million in Q1 2026, -$4.1 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -4.06 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Mar 31, 2025 | 11.98 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -2.39 Mn |
| Dec 31, 2023 | -4.55 Mn |
| Sep 30, 2023 | -5.47 Mn |